THROUGH UNIVERSITY RESEARCH AND DEVELOPMENT
With a scientific team at Western University, CanaQuest Medical Corp has created a few CREATIVE patentable product formulations. Our research and product development focuses on health products utilizing cannabis isolates and botanical compounds, including algae oils (pharmaceutical grade).
To learn more about our value proposition and the benefits of our commercial-ready products, view the full presentation on the Investors page or by clicking the thumbnail graphic further down.
Click picture above to see full-sized image.
CanaQuest Store
Visit our online store to pre-register or subscribe for information.
Investor Presentation
Our corporate introduction document provides a comprehensive summary of CanaQuest today and its many opportunities for the future.
Click picture above to see the full presentation.
PRODUCT FORMULATIONS
A critical mass of clinical evidence regarding the efficacy of medical cannabis is refuting political, scientific, and other skeptics, and opening minds hardened by decades of anti-cannabis propaganda. Our goal is to develop better alternative treatments to traditional pharmaceuticals for people struggling with a variety of health challenges.
CQ1 (Mentabinol®)
Commercial Ready
(THC + formula)
Supports mental health: Anxiety, depression, and schizophrenia.
CQ2 (Mentanine®)
Commercial Ready
(Omega 3 + formula)
Supports mental health: Anxiety, depression, PTSD and addiction.
CQ3 (Mentanine – pain®)
Commercial Ready
(Omega 3 + formula)
To support endocannabinoid system health: Inflammation and pain.
CQ4 (Menata…®)
Coming soon
(More details to be released)
To support mental health: Alzheimer’s.
FOCUS AREAS
Anxiety
Addiction
Depression
Schizophrenia
PTSD
Chronic Pain
OUR VISION
Our vision is to be a global leader in the formulation and development of health products from cannabis derivatives.
IN THE NEWS
CanaQuest Files International Mentanine(R) Patent, a Scientific CBD Formulation for Mental Health
TORONTO, ON / April 29, 2021 -- CANAQUEST MEDICAL CORP (OTC PINK:CANQF) (the "Company" or "CanaQuest"), an award-winning Life Science/Pharmaceutical company developing formulations combining cannabinoid molecules with pharmaceutical-grade botanical compounds, today announced the filing of its International [...]
CanaQuest Medical Corp Appoints Investor Relations and PR Veteran Rob Rinderman as its New Director of Communications
TORONTO, ON / April 7, 2021 -- CANAQUEST MEDICAL CORP (OTC PINK:CANQF) (the "Company" or "CanaQuest"), an award-winning Life Science/Pharmaceutical company developing health and wellness products combining cannabinoid molecules with pharmaceutical-grade botanical compounds, today announced that Rob Rinderman [...]
CanaQuest Medical Corp Honored With International CBD Life Science R & D Excellence Award 2020 by Global Health & Pharma
TORONTO, ON / March 30, 2021 -- CANAQUEST MEDICAL CORP (OTC PINK:CANQF) (the "Company" or "CanaQuest"), a Life Science/Pharmaceutical Company developing health products utilizing cannabinoid molecules and other botanical compounds (pharmaceutical grade), today announced it has been [...]